Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Johnson and Johnson...

    Johnson and Johnson Baby Powder litigation takes new focus with asbestos claims

    Written by Ruby Khatun Khatun Published On 2018-04-17T09:30:49+05:30  |  Updated On 17 April 2018 9:30 AM IST
    Johnson and Johnson Baby Powder litigation takes new focus with asbestos claims

    NEW YORK: A $117 million verdict against Johnson and Johnson and a supplier in favor of a man who said his asbestos-related cancer was caused by long-term use of J&J’s Baby Powder could open a new front for thousands of cases claiming the widely-used product caused cancer, legal experts, and plaintiffs lawyers said.


    J&J has been battling some 6,000 cases claiming its baby powder and Shower to Shower products cause ovarian cancer. The $117 million verdict by a New Jersey jury last week, however, involved a different form of cancer that is clearly linked to asbestos.


    Plaintiffs lawyers claim that internal J&J documents seen in that trial show that baby powder had been contaminated with asbestos. They now plan to use the documents in upcoming ovarian cancer trials to allege that the asbestos contamination also caused that form of cancer.


    J&J and Imerys Talc America, a unit of Imerys SA, have vowed to appeal the New Jersey verdict and deny asbestos has ever been present in their products or that their talc can cause any form of cancer.


    The case of Stephen Lanzo, a New Jersey resident who claimed he developed mesothelioma after using baby powder since his birth in 1972, was the first time a jury saw the internal J&J documents which plaintiffs claim show that J&J knew since the 1970s that the talc in its baby powder was contaminated by asbestos during the mining process.


    J&J says the documents present no such evidence, but merely show the company’s caution.


    Peter Bicks, a lawyer leading J&J’s talc asbestos defense, said that in the early 1970s, the company was looking at how it could potentially remove asbestos from talc if the two became intermingled in the mining process. He says no contamination was ever found, citing decades of testing by independent laboratories and scientists.


    Bicks called the claims of a link between talc and asbestos “junk science.”


    Mesothelioma, a rare and deadly form of cancer closely associated with exposure to asbestos, affects the delicate tissue that lines body cavities.


    While the link between asbestos and mesothelioma is sufficiently established, scientists are divided on whether asbestos exposure can cause ovarian cancer. Some studies have shown an association between the two, while other studies have found no such link.








    Elizabeth Burch, a holder of the Charles H. Kirbo Chair of Law at the University of Georgia, said it remained an open question whether talc contained asbestos and that each case would turn on the facts.






    But J&J, which had $76.5 billion in sales in 2017, gives the plaintiffs’ bar an enticing new target, said Nathan Schachtman, a lecturer at Columbia University who used to defend asbestos cases.


    Some 3,000 people are diagnosed with mesothelioma each year, according to the American Cancer Society, a number that Howard Erichson, a law professor at Fordham University who specializes in mass tort litigation, called significant from a legal standpoint.


    But the roughly 22,000 women who were diagnosed with ovarian cancer last year, according to the National Cancer Institute, provide lawyers with a potentially much larger pool of plaintiffs to tap.


    “This is just the tip of the iceberg,” said Mark Lanier, one of the lawyers representing consumers, who said plaintiffs would file thousands of additional mesothelioma and ovarian cancer cases.


    New Jersey-based J&J in a statement after the Lanzo verdict said plaintiffs’ attorneys had shifted their strategy to focus on asbestos after a series of losses at trial and in court rulings over previous allegations that the talc itself causes cancer.


    Of the six ovarian cancer trials to date, juries found J&J liable five times, but a Missouri appellate court threw out the first verdict and a California judge tossed another. Appeals of the other cases are pending.


    J&J in November also won the first trial over allegations that its talc contained asbestos and caused a woman’s mesothelioma. Plaintiffs lawyers say the jury, in that case, did not see the documents presented during the Lanzo trial.




    But Erichson said the widespread use of J&J’s consumer products generally makes the company an attractive litigation target.


    “Baby powder is as ubiquitous a product you can think of and there are lots of people who can testify they’ve been exposed to it,” he said.





    (Reporting by Tina Bellon; editing by Noeleen Walder and Leslie Adler)




    asbestosbaby powdercancerImerysImerys TalcJohnson and Johnsonlitigationovarian cancerverdict
    Source : REUTERS

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Ruby Khatun Khatun
    Ruby Khatun Khatun
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok